Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Editorial

Suppression of bone morphogenetic protein inhibitors promotes osteogenic differentiation: therapeutic implications

Manolis Heliotis1 and Eleftherios Tsiridis2*

Author Affiliations

1 Regional North West London Maxillofacial Unit, Northwick Park Hospital, Wattford Road, Harrow, London HA1 3UJ, UK

2 Academic Orthopaedic Unit, Institute of Molecular Medicine, Leeds Medical School, and Leeds General Infirmary Teaching Hospital, Clarendon, Great George Street, Leeds LS1 3EX, UK

For all author emails, please log on.

Arthritis Research & Therapy 2008, 10:115  doi:10.1186/ar2467


See related research by Kwong et al., http://arthritis-research.com/content/10/3/R65

Published: 12 August 2008

Abstract

Bone morphogenetic proteins (BMPs) are expressed during osteogenesis and their action is regulated by corresponding BMP inhibitors. Chordin (a well recognized BMP inhibitor) and BMP-2 are expressed during osteogenic differentiation of human mesenchymal stem cells. Chordin inhibition induces human mesenchymal stem cell differentiation and reduces their proliferation by increasing BMP-2 bioavailability. The potential of suppressing BMP inhibitors is emerging as a biological therapeutic target in bone tissue engineering, because it results in an unopposed synergy between the various growth factors that are involved in osteogenesis, within their physiological milieu.